[go: up one dir, main page]

MX2024011265A - Metodos, regimenes de dosificacion, y composiciones para el tratamiento de hidradenitis. - Google Patents

Metodos, regimenes de dosificacion, y composiciones para el tratamiento de hidradenitis.

Info

Publication number
MX2024011265A
MX2024011265A MX2024011265A MX2024011265A MX2024011265A MX 2024011265 A MX2024011265 A MX 2024011265A MX 2024011265 A MX2024011265 A MX 2024011265A MX 2024011265 A MX2024011265 A MX 2024011265A MX 2024011265 A MX2024011265 A MX 2024011265A
Authority
MX
Mexico
Prior art keywords
compositions
methods
dosage regimens
treating hidradenitis
treating
Prior art date
Application number
MX2024011265A
Other languages
English (en)
Inventor
Brian Stephen Gerstenberger
Dafydd Rhys Owen
Andrew Fensome
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2024011265A publication Critical patent/MX2024011265A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Existen métodos, régimenes de dosificación y composiciones para el tratamiento de hidradenitis supurativa.
MX2024011265A 2022-03-17 2023-03-08 Metodos, regimenes de dosificacion, y composiciones para el tratamiento de hidradenitis. MX2024011265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263320913P 2022-03-17 2022-03-17
PCT/US2023/063938 WO2023178001A1 (en) 2022-03-17 2023-03-08 Methods, dosage regimens, and compositions for treating hidradenitis

Publications (1)

Publication Number Publication Date
MX2024011265A true MX2024011265A (es) 2024-09-23

Family

ID=88024423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011265A MX2024011265A (es) 2022-03-17 2023-03-08 Metodos, regimenes de dosificacion, y composiciones para el tratamiento de hidradenitis.

Country Status (10)

Country Link
US (1) US20230293544A1 (es)
EP (1) EP4493191A1 (es)
JP (1) JP2025509615A (es)
KR (1) KR20240162125A (es)
CN (1) CN118973579A (es)
AU (1) AU2023233663A1 (es)
CA (1) CA3244887A1 (es)
IL (1) IL314981A (es)
MX (1) MX2024011265A (es)
WO (1) WO2023178001A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040545B2 (en) * 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
NO2721710T3 (es) * 2014-08-21 2018-03-31
SG11201907159SA (en) * 2017-02-16 2019-09-27 Xbiotech Inc Treatment of hidradenitis suppurativa
KR20220059519A (ko) * 2019-09-11 2022-05-10 화이자 인코포레이티드 키나제 억제제에 의한 한선염의 치료

Also Published As

Publication number Publication date
KR20240162125A (ko) 2024-11-14
AU2023233663A1 (en) 2024-09-05
US20230293544A1 (en) 2023-09-21
JP2025509615A (ja) 2025-04-11
EP4493191A1 (en) 2025-01-22
CA3244887A1 (en) 2023-09-21
WO2023178001A1 (en) 2023-09-21
CN118973579A (zh) 2024-11-15
IL314981A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
GEAP202315703A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CR20190478A (es) Inhibidores de pd-1/pd-l1
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12022550130A1 (en) Enzyme inhibitors
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2023006551A (es) Tratamiento de las convulsiones refractarias.
WO2021163654A8 (en) Rnas for complement inhibition
PH12022551468A1 (en) Compounds active towards nuclear receptors
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
GB202412566D0 (en) Certain N-(1-cynao-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
WO2021038296A3 (en) Modified tff2 polypeptides
MX2025010397A (es) Compuestos heterociclicos como inhibidores de la helicasa del sindrome de werner (wrn)
CR20230294A (es) Método para preparar pralsetinib
MX2024001888A (es) Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
WO2019204332A3 (en) Pak4 inhibitors and methods of use
WO2021211784A3 (en) Method of treating coronavirus infections
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
MX2024011265A (es) Metodos, regimenes de dosificacion, y composiciones para el tratamiento de hidradenitis.
ZA202209970B (en) Neurotoxin compositions for use in treating cardiovascular disorders
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood
MX2023005171A (es) Composiciones y metodos para tratamiento de cancer solido.